<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcmedphys&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Medical Physics - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcmedphys/</link>
        <description>The latest research articles published by BMC Medical Physics</description>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/13/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/13/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/12/4" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/12/3" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/12/2" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/12/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/11/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/10/1" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/9/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1756-6649/9/5" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/13/2">
        <title>Dose mapping sensitivity to deformable registration uncertainties in fractionated radiotherapy -- applied to prostate proton treatments</title>
        <description>Background:
Calculation of accumulated dose in fractionated radiotherapy based on spatial mapping of the dose points generally requires deformable image registration (DIR). The accuracy of the accumulated dose thus depends heavily on the DIR quality. This motivates investigations of how the registration uncertainty influences dose planning objectives and treatment outcome predictions.A framework was developed where the dose mapping can be associated with a variable known uncertainty to simulate the DIR uncertainties in a clinical workflow. The framework enabled us to study the dependence of dose planning metrics, and the predicted treatment outcome, on the DIR uncertainty. The additional planning margin needed to compensate for the dose mapping uncertainties can also be determined. We applied the simulation framework to a hypofractionated proton treatment of the prostate using two different scanning beam spot sizes to also study the dose mapping sensitivity to penumbra widths.
Results:
The planning parameter most sensitive to the DIR uncertainty was found to be the target D95. We found that the registration mean absolute error needs to be &lt;=0.20 cm to obtain an uncertainty better than 3% of the calculated D95 for intermediate sized penumbras. Use of larger margins in constructing PTV from CTV relaxed the registration uncertainty requirements to the cost of increased dose burdens to the surrounding organs at risk.
Conclusions:
The DIR uncertainty requirements should be considered in an adaptive radiotherapy workflow since this uncertainty can have significant impact on the accumulated dose. The simulation framework enabled quantification of the accuracy requirement for DIR algorithms to provide satisfactory clinical accuracy in the accumulated dose.</description>
        <link>http://www.biomedcentral.com/1756-6649/13/2</link>
                <dc:creator>David Tilly</dc:creator>
                <dc:creator>Nina Tilly</dc:creator>
                <dc:creator>Anders Ahnesjö</dc:creator>
                <dc:source>BMC Medical Physics 2013, null:2</dc:source>
        <dc:date>2013-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-13-2</dc:identifier>
                                <prism:require>/content/figures/1756-6649-13-2-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2013-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/13/1">
        <title>The 2D Hotelling filter - a quantitative noise-reducing principal-component filter for dynamic PET data, with applications in patient dose reduction</title>
        <description>Background:
In this paper we apply the principal-component analysis filter (Hotelling filter) to reduce noise from dynamic positron-emission tomography (PET) patient data, for a number of different radio-tracer molecules. We furthermore show how preprocessing images with this filter improves parametric images created from such dynamic sequence.We use zero-mean unit variance normalization, prior to performing a Hotelling filter on the slices of a dynamic time-series. The Scree-plot technique was used to determine which principal components to be rejected in the filter process. This filter was applied to [11C]-acetate on heart and head-neck tumors, [18F]-FDG on liver tumors and brain, and [11C]-Raclopride on brain. Simulations of blood and tissue regions with noise properties matched to real PET data, was used to analyze how quantitation and resolution is affected by the Hotelling filter. Summing varying parts of a 90-frame [18F]-FDG brain scan, we created 9-frame dynamic scans with image statistics comparable to 20 MBq, 60 MBq and 200 MBq injected activity. Hotelling filter performed on slices (2D) and on volumes (3D) were compared.
Results:
The 2D Hotelling filter reduces noise in the tissue uptake drastically, so that it becomes simple to manually pick out regions-of-interest from noisy data. 2D Hotelling filter introduces less bias than 3D Hotelling filter in focal Raclopride uptake. Simulations show that the Hotelling filter is sensitive to typical blood peak in PET prior to tissue uptake have commenced, introducing a negative bias in early tissue uptake. Quantitation on real dynamic data is reliable. Two examples clearly show that pre-filtering the dynamic sequence with the Hotelling filter prior to Patlak-slope calculations gives clearly improved parametric image quality. We also show that a dramatic dose reduction can be achieved for Patlak slope images without changing image quality or quantitation.
Conclusions:
The 2D Hotelling-filtering of dynamic PET data is a computer-efficient method that gives visually improved differentiation of different tissues, which we have observed improve manual or automated region-of-interest delineation of dynamic data. Parametric Patlak images on Hotelling-filtered data display improved clarity, compared to non-filtered Patlak slope images without measurable loss of quantitation, and allow a dramatic decrease in patient injected dose.</description>
        <link>http://www.biomedcentral.com/1756-6649/13/1</link>
                <dc:creator>Jan Axelsson</dc:creator>
                <dc:creator>Jens Sörensen</dc:creator>
                <dc:source>BMC Medical Physics 2013, null:1</dc:source>
        <dc:date>2013-04-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-13-1</dc:identifier>
                                <prism:require>/content/figures/1756-6649-13-1-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2013-04-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/12/4">
        <title>Multiscale forward electromagnetic model of uterine contractions during pregnancy</title>
        <description>Background:
Analyzing and monitoring uterine contractions during pregnancy is relevant to the field of reproductive health assessment. Its clinical importance is grounded in the need to reliably predict the onset of labor at term and pre-term. Preterm births can cause health problems or even be fatal for the fetus. Currently, there are no objective methods for consistently predicting the onset of labor based on sensing of the mechanical or electrophysiological aspects of uterine contractions. Therefore, modeling uterine contractions could help to better interpret such measurements and to develop more accurate methods for predicting labor. In this work, we develop a multiscale forward electromagnetic model of myometrial contractions during pregnancy. In particular, we introduce a model of myometrial current source densities and compute its magnetic field and action potential at the abdominal surface, using Maxwell&#8217;s equations and a four-compartment volume conductor geometry. To model the current source density at the myometrium we use a bidomain approach. We consider a modified version of the Fitzhugh-Nagumo (FHN) equation for modeling ionic currents in each myocyte, assuming a plateau-type transmembrane potential, and we incorporate the anisotropic nature of the uterus by designing conductivity-tensor fields.
Results:
We illustrate our modeling approach considering a spherical uterus and one pacemaker located in the fundus. We obtained a travelling transmembrane potential depolarizing from &#8722;56 mV to &#8722;16 mV and an average potential in the plateau area of &#8722;25 mV with a duration, before hyperpolarization, of 35 s, which is a good approximation with respect to the average recorded transmembrane potentials at term reported in the technical literature. Similarly, the percentage of myometrial cells contracting as a function of time had the same symmetric properties and duration as the intrauterine pressure waveforms of a pregnant human myometrium at term.
Conclusions:
We introduced a multiscale modeling approach of uterine contractions which allows for incorporating electrophysiological and anatomical knowledge of the myometrium jointly. Our results are in good agreement with the values reported in the experimental technical literature, and these are potentially important as a tool for helping in the characterization of contractions and for predicting labor using magnetomyography (MMG) and electromyography (EMG).</description>
        <link>http://www.biomedcentral.com/1756-6649/12/4</link>
                <dc:creator>Patricio La Rosa</dc:creator>
                <dc:creator>Hari Eswaran</dc:creator>
                <dc:creator>Hubert Preissl</dc:creator>
                <dc:creator>Arye Nehorai</dc:creator>
                <dc:source>BMC Medical Physics 2012, null:4</dc:source>
        <dc:date>2012-11-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-12-4</dc:identifier>
                                <prism:require>/content/figures/1756-6649-12-4-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-11-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/12/3">
        <title>The study of radiosensitivity in left handed compared to right handed healthy women</title>
        <description>Background:
Radiosensitivity is an inheriting trait that mainly depends on genetic factors. it is well known in similar dose of ionizing radiation and identical biological characteristics 9&#8211;10 percent of normal population have higher radiation response. Some reports indicate that distribution of breast cancer, immune diseases including autoimmune diseases as example lupus, Myasthenia Gravies and even the rate of allergy are more frequent in left handed individuals compared to right handed individuals. The main goal of the present study is determination of radiosensitivity in left handed compared to right handed in healthy women by cytokinesis blocked micronuclei [CBMN] assay.5 ml peripheral fresh blood sample was taken from 100 healthy women including 60 right handed and 40 left handed. The age of participants was between 20&#8211;25 old years and they had been matched by sex. After blood sampling, blood samples were divided to 2 groups including irradiated and non-irradiated lymphocytes that irradiated lymphocytes were exposed to 2 Gy CO-60 Gama rays source then chromosomal aberrations was analyzed by CBMN [Cytokinesis Blocked Micronuclei Assay].
Results:
Our results have shown radiosensitivity index [RI] in left-handers compared to right-handers is higher. Furthermore, the mean MN frequency is elevated in irradiated lymphocytes of left-handers in comparison with right-handers.
Conclusion:
Our results from CBMN assay have shown radiosensitivity in the left handed is higher than right handed women but more attempts need to prove this hypothesis.</description>
        <link>http://www.biomedcentral.com/1756-6649/12/3</link>
                <dc:creator>Meysam Khosravifarsani</dc:creator>
                <dc:creator>Ali Shabestani Monfared</dc:creator>
                <dc:creator>Haleh Akhavan Niaki</dc:creator>
                <dc:creator>Dariush Moslemi</dc:creator>
                <dc:creator>Karimollah Hajian-Tilaki</dc:creator>
                <dc:creator>Faridehelahimanesh Elahimanesh</dc:creator>
                <dc:creator>Sajad Borzoueisileh</dc:creator>
                <dc:creator>Nayer Seyfizadeh</dc:creator>
                <dc:creator>Mehrangiz Amiri</dc:creator>
                <dc:source>BMC Medical Physics 2012, null:3</dc:source>
        <dc:date>2012-08-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-12-3</dc:identifier>
                                <prism:require>/content/figures/1756-6649-12-3-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-08-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/12/2">
        <title>Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma</title>
        <description>Background:
Intensity modulated radiotherapy is an efficient radiotherapy technique to increase dose in target volumes and decrease irradiation dose in organs at risk. This last objective is mainly relevant in children. However, previous results suggested that IMRT could increase low dose, factor of risk for secondary radiation induced cancer. This study was performed to compare dose distributions with 3D-radiotherapy (3D-RT) and IMRT with tomotherapy (HT) in children with neuroblastoma. Seven children with neuroblastoma were irradiated. Treatment plans were calculated for 3D-RT, and for HT. For the volume of interest, the PTV-V95% and conformity index were calculated. Dose constraints of all the organs at risk and integral dose were compared.
Results:
The conformity index was statistically better for HT than for 3D-RT. PTV-V95% constraint was reached in 6 cases with HT compared to 2 cases with 3D-RT. For the ipsilateral kidney of the tumor, the V12 Gy constraint was reached for 3 patients with both methods. The values were lower with HT than with 3D-RT in two cases and higher in one case. The threshold was not reached for one patient with either technique, but the value was lower with HT than with 3D-RT. For the contralateral kidney of the tumors, the V12 Gy constraint was reached for all patients with both methods. The values were lower with HT than with 3D-RT in 5 of 7 children, equal in one patient and higher in one patient. The organ-at-risk volumes receiving low doses were significantly lower with 3D-RT but larger for the highest doses, compared to those irradiated with HT. The integral doses were not different.
Conclusions:
IMRT with HT allows a better conformity treatment, a more frequently acceptable PTV-V95% than 3D-RT and, concomitantly, a better shielding of the kidneys. The integral doses are comparable between both techniques but consideration of differences in dose distribution between the two techniques, for the organs at risk, has to be taken in account when validating treatment.</description>
        <link>http://www.biomedcentral.com/1756-6649/12/2</link>
                <dc:creator>Violaine Beneyton</dc:creator>
                <dc:creator>Claudine Niederst</dc:creator>
                <dc:creator>Céline Vigneron</dc:creator>
                <dc:creator>Philippe Meyer</dc:creator>
                <dc:creator>François Becmeur</dc:creator>
                <dc:creator>Luc Marcellin</dc:creator>
                <dc:creator>Patrick Lutz</dc:creator>
                <dc:creator>Georges Noel</dc:creator>
                <dc:source>BMC Medical Physics 2012, null:2</dc:source>
        <dc:date>2012-06-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-12-2</dc:identifier>
                                <prism:require>/content/figures/1756-6649-12-2-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-06-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/12/1">
        <title>Navigator channel adaptation to reconstruct three dimensional heart volumes from two dimensional radiotherapy planning data</title>
        <description>Background:
Biologically-based models that utilize 3D radiation dosimetry data to estimate the risk of late cardiac effects could have significant utility for planning radiotherapy in young patients. A major challenge arises from having only 2D treatment planning data for patients with long-term follow-up. In this study, we evaluate the accuracy of an advanced deformable image registration (DIR) and navigator channels (NC) adaptation technique to reconstruct 3D heart volumes from 2D radiotherapy planning images for Hodgkin&apos;s Lymphoma (HL) patients.
Methods:
Planning CT images were obtained for 50 HL patients who underwent mediastinal radiotherapy. Twelve image sets (6 male, 6 female) were used to construct a male and a female population heart model, which was registered to 23 HL &quot;Reference&quot; patients&apos; CT images using a DIR algorithm, MORFEUS. This generated a series of population-to-Reference patient specific 3D deformation maps. The technique was independently tested on 15 additional &quot;Test&quot; patients by reconstructing their 3D heart volumes using 2D digitally reconstructed radiographs (DRR). The technique involved: 1) identifying a matching Reference patient for each Test patient using thorax measurements, 2) placement of six NCs on matching Reference and Test patients&apos; DRRs to capture differences in significant heart curvatures, 3) adapting the population-to-Reference patient-specific deformation maps to generate population-to-Test patient-specific deformation maps using linear and bilinear interpolation methods, 4) applying population-to-Test patient specific deformation to the population model to reconstruct Test-patient specific 3D heart models. The percentage volume overlap between the NC-adapted reconstruction and actual Test patient&apos;s true heart volume was calculated using the Dice coefficient.
Results:
The average Dice coefficient expressed as a percentage between the NC-adapted and actual Test model was 89.4 &#177; 2.8%. The modified NC adaptation technique made significant improvements to the population deformation heart models (p = 0.01). As standard evaluation, the residual Dice error after adaptation was comparable to the volumetric differences observed in free-breathing heart volumes (p = 0.62).
Conclusions:
The reconstruction technique described generates accurate 3D heart models from limited 2D planning data. This development could potentially be used to retrospectively calculate delivered dose to the heart for historically treated patients and thereby provide a better understanding of late radiation-related cardiac effects.</description>
        <link>http://www.biomedcentral.com/1756-6649/12/1</link>
                <dc:creator>Angela Ng</dc:creator>
                <dc:creator>Thao-Nguyen Nguyen</dc:creator>
                <dc:creator>Joanne Moseley</dc:creator>
                <dc:creator>David Hodgson</dc:creator>
                <dc:creator>Michael Sharpe</dc:creator>
                <dc:creator>Kristy Brock</dc:creator>
                <dc:source>BMC Medical Physics 2012, null:1</dc:source>
        <dc:date>2012-01-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-12-1</dc:identifier>
                            <dc:title>Reconstructing 3D heart volumes from 2D data</dc:title>
                            <dc:description>Navigator channel adaptation techniques generate accurate 3D heart models from limited 2D planning data; the technique has potential to improve long-term treatment for patients who lack historical 3D radiation dosimetry data.</dc:description>
                <prism:require>/content/figures/1756-6649-12-1-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/11/1">
        <title>Preclinical multimodality phantom design for quality assurance of tumor size measurement</title>
        <description>Background:
Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.
Methods:
Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed.
Results:
The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (&#8804;1.69 &#177; 0.33%) compared with both Mark 1 (&#8804; -7.56 &#177; 6.52%) and Mark 2 (&#8804; 5.66 &#177; 1.41%) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p &lt; 0.0001), CT (R2 = 0.9999, p &lt; 0.0001) and MRI (R2 = 0.9998, p &lt; 0.0001).
Conclusions:
The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.</description>
        <link>http://www.biomedcentral.com/1756-6649/11/1</link>
                <dc:creator>Yongsook Lee</dc:creator>
                <dc:creator>Gary Fullerton</dc:creator>
                <dc:creator>Cristel Baiu</dc:creator>
                <dc:creator>Margaret Lescrenier</dc:creator>
                <dc:creator>Beth Goins</dc:creator>
                <dc:source>BMC Medical Physics 2011, null:1</dc:source>
        <dc:date>2011-09-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-11-1</dc:identifier>
                            <dc:title>Multimodal phantom for tumor size measurement</dc:title>
                            <dc:description>A multimodal tumor measurement phantom was designed, and test results indicate that it could serve as a useful quality assurance tool in assessing tumor size change across multiple imaging modalities.</dc:description>
                <prism:require>/content/figures/1756-6649-11-1-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2011-09-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/10/1">
        <title>Theoretical generalization of normal and sick coronary arteries with fractal dimensions and the arterial intrinsic mathematical harmony</title>
        <description>Background:
Fractal geometry is employ to characterize the irregular objects and had been used in experimental and clinic applications. Starting from a previous work, here we made a theoretical research based on a geometric generalization of the experimental results, to develop a theoretical generalization of the stenotic and restenotic process, based on fractal geometry and Intrinsic Mathematical Harmony.
Methods:
Starting from all the possibilities of space occupation in box-counting space, all arterial prototypes differentiating normality and disease were obtained with a computational simulation. Measures from 2 normal and 3 re-stenosed arteries were used as spatial limits of the generalization.
Results:
A new methodology in animal experimentation was developed, based on fractal geometric generalization. With this methodology, it was founded that the occupation space possibilities in the stenotic process are finite and that 69,249 arterial prototypes are obtained as a total.
Conclusions:
The Intrinsic Mathematical Harmony reveals a supra-molecular geometric self-organization, where the finite and discrete fractal dimensions of arterial layers evaluate objectively the arterial stenosis and restenosis process.</description>
        <link>http://www.biomedcentral.com/1756-6649/10/1</link>
                <dc:creator>Javier Rodriguez</dc:creator>
                <dc:creator>Signed Prieto</dc:creator>
                <dc:creator>Catalina Correa</dc:creator>
                <dc:creator>Pedro Bernal</dc:creator>
                <dc:creator>German Puerta</dc:creator>
                <dc:creator>Sarith Vitery</dc:creator>
                <dc:creator>Yolanda Soracipa</dc:creator>
                <dc:creator>Diana Munoz</dc:creator>
                <dc:creator>Insight Group</dc:creator>
                <dc:source>BMC Medical Physics 2010, null:1</dc:source>
        <dc:date>2010-09-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-10-1</dc:identifier>
                                <prism:require>/content/figures/1756-6649-10-1-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-09-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/9/6">
        <title>Differential radio-sensitivities of human chromosomes 1 and 2 in one donor in interphase- and metaphase-spreads after 60Co gamma-irradiation</title>
        <description>Background:
Radiation-induced chromosome aberrations lead to a plethora of detrimental effects at cellular level. Chromosome aberrations provide broad spectrum of information ranging from probability of malignant transformation to assessment of absorbed dose. Studies mapping differences in radiation sensitivities between human chromosomes are seldom undertaken. Consequently, health risk assessment based on radio-sensitivities of individual chromosomes may be erroneous. Our efforts in this article, attempt to demonstrate differences in radio-sensitivities of human chromosome-1 and/or -2, both in interphase and metaphase spreads.
Methods:
Upon blood collection, dosimetry and irradiation were performed. Lymphocytes were isolated after whole-blood irradiation with 60Co &#947;-rays in the dose range of 0&#8211;5 Gy for both interphase, and metaphase aberration studies. Induction of premature chromosome condensation in interphase cells was accomplished using a phosphatase inhibitor, calyculin-A. Metaphase spreads were harvested from short-term peripheral blood lymphocyte cultures following colcemid arrest and using an automated metaphase harvester and spreader. Aberration analysis in both interphase and metaphase spreads were done using FISH.
Results:
In interphase, aberrant cell and aberration frequency involving chromosome 1 and/or 2 increased linearly with radiation dose. In metaphase, aberrations increased in a linear-quadratic manner with dose. Our studies ascertain that chromosome-2 is more radio-sensitive than chromosome-1 in both interphase and metaphase stages, albeit the DNA content of chromosome-2 is lesser than chromosome-1 by almost 10 million base pairs.
Conclusion:
Differences in radio-sensitivities of chromosomes have implications in genetic damage, chromosome organization, and chromosome function. Designing research experiments based on our vital findings may bring benefit to radiation-induced risk assessment, therapeutics and development of chromosome specific biomarkers.</description>
        <link>http://www.biomedcentral.com/1756-6649/9/6</link>
                <dc:creator>Rupak Pathak</dc:creator>
                <dc:creator>Adarsh Ramakumar</dc:creator>
                <dc:creator>Uma Subramanian</dc:creator>
                <dc:creator>Pataje Prasanna</dc:creator>
                <dc:source>BMC Medical Physics 2009, null:6</dc:source>
        <dc:date>2009-06-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-9-6</dc:identifier>
                            <dc:title>Different radiosensitivities of chromosomes 1 and 2</dc:title>
                            <dc:description>Chromosome 2 may be more sensitive to radiation-induced damage than chromosome 1 during both interphase and metaphase; use of radiosensitivity differences has implications for radiation-induced health risk assessment.</dc:description>
                <prism:require>/content/figures/1756-6649-9-6-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2009-06-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1756-6649/9/5">
        <title>Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up</title>
        <description>Background:
Light chain amyloidosis (AL) is a rare plasma cell dyscrasia associated with poor survival especially in the setting of heart failure. Late gadolinium enhancement (LGE) on cardiac MRI was recently found to correlate with myocardial amyloid deposition but the prognostic role is not established. The aim is to determine the prognostic significance of LGE in AL by comparing long term survival of AL patients with and without LGE.
Methods:
Twenty nine consecutive patients (14 females; 62 &#177; 11 years) with biopsy-proven AL undergoing cardiac MRI with gadolinium as part of AL workup were included. Survival was prospectively followed 29 months (median) following MRI and compared between those with and without LGE by Kaplan-Meier and log-rank analyses.
Results:
LGE was positive in 23 subjects (79%) and negative in 6 (21%). Left ventricular ejection fraction was 66 &#177; 17% in LGE-positive and 69 &#177; 12% in LGE-negative patients (p = 0.8). Overall 1-year mortality was 36%. On follow-up, 14/23 LGE-positive and none of LGE-negative patients died (log rank p = 0.0061). Presenting New York Heart Association heart failure class was also associated with poor survival (p = 0.0059). Survival between two LGE groups stratified by heart failure class still showed a significant difference by a stratified log-rank test (p = 0.04).
Conclusion:
Late gadolinium enhancement is common and is associated with poor long-term survival in light chain amyloidosis, even after adjustment for heart failure class presentation. The prognostic significance of late gadolinium enhancement in this disease may be useful in patient risk-stratification.</description>
        <link>http://www.biomedcentral.com/1756-6649/9/5</link>
                <dc:creator>Raymond Migrino</dc:creator>
                <dc:creator>Richard Christenson</dc:creator>
                <dc:creator>Aniko Szabo</dc:creator>
                <dc:creator>Megan Bright</dc:creator>
                <dc:creator>Seth Truran</dc:creator>
                <dc:creator>Parameswaran Hari</dc:creator>
                <dc:source>BMC Medical Physics 2009, null:5</dc:source>
        <dc:date>2009-05-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6649-9-5</dc:identifier>
                                <prism:require>/content/figures/1756-6649-9-5-toc.gif</prism:require>
                <prism:publicationName>BMC Medical Physics</prism:publicationName>
        <prism:issn>1756-6649</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-05-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
